Stronger warning about potential hepatotoxicity in patients taking Duract (bromfenac)
The FDA is requiring a stronger warning about potential hepatotoxicity in patients taking Duract (bromfenac). Duract is the new NSAID that just came out last fall. It's approved only for short-term use...similar to Toradol (ketorolac).
Now there are several reports of severe hepatitis and liver failure in patients taking Duract for longer than a month.
Don't prescribe Duract for more than 10 days. If patients take it longer, monitor LFTs...particularly ALT and bilirubin.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote